News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Deucravacitinib bests placebo, apremilast in moderate-to-severe plaque psoriasis
01 Oct 2022
Treatment with deucravacitinib achieves better efficacy than placebo and apremilast in patients with moderate-to-severe plaque psoriasis, while also yielding a good safety profile, reports a recent study.
01 Oct 2022

Absence of standard modifiable cardiovascular risk factors tied to poor outcomes in type 2 AMI
01 Oct 2022
Among patients with type 2 acute myocardial infarction (AMI), the absence of standard modifiable cardiovascular risk factors (SMuRF) appears to worsen poor outcomes, such as mortality, stroke, and major adverse cardiovascular and cerebrovascular events (MACCE), a new study has found.
01 Oct 2022






